Evidence map›Paper›PMID 35662218›Full record

ArticleNeural regeneration research2022

Necrostatin-1 decreases necroptosis and inflammatory markers after intraventricular hemorrhage in mice.

Chang Liu, Yi Cao, Hao-Xiang Wang, Long Zhao, Ya-Xing Chen, Kun-Hong Zhong, Gao-Wei Li, Guo-Qing Wang, Ke-Ru Huang, Ai-Ping Tong and 1 more

Open access · goldAbstract read
In one paragraph

Article in Neural regeneration research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Programmed cardiomyocyte death in myocardial infarction.Apoptosis : an international journal on programmed cell death · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Necrostatin-1: a promising compound for neurological disorders.Frontiers in cellular neuroscience · 2024
    Review
  9. Review
  10. Advances in RIPK1 kinase inhibitors.Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chang LiuDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Yi CaoDepartment of Neurosurgery, Chengdu Second People's Hospital, Chengdu, Sichuan Province, China.
Hao-Xiang WangDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Long ZhaoDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu; Department of Neurosurgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China.
Ya-Xing ChenDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Kun-Hong ZhongState Key Laboratory of Biotherapy, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.
Gao-Wei LiDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Guo-Qing WangDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Ke-Ru HuangDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Ai-Ping TongState Key Laboratory of Biotherapy, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.
Liang-Xue ZhouDepartment of Neurosurgery, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Sichuan University · CNChengdu Second People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necrostatin-1, an inhibitor of necroptosis, can effectively inhibit necrotic apoptosis in neurological diseases, which results in the inhibition of inflammation, endoplasmic reticulum stress, and reactive oxygen species production and substantial improvement of neurological function. However, the effects of necrostatin-1 on intraventricular hemorrhage (IVH) remain unknown. In this study, we established a mouse model of IVH by injecting autologous blood into the lateral ventricle of the brain. We also injected necrostatin-1 into the lateral ventricle one hour prior to IVH induction. We found that necrostatin-1 effectively reduced the expression levels of the necroptosis markers receptor-interacting protein kinase (RIP)1, RIP3, mixed lineage kinase domain-like protein (MLKL), phosphorylated (p)-RIP3, and p-MLKL and the levels of interleukin-1β , interleukin-6, and tumor necrosis factor-α in the surrounding areas of the lateral ventricle. However, necrostatin-1 did not reduce ependymal ciliary injury or brain water content. These findings suggest that necrostatin-1 can prevent local inflammation and microglial activation induced by IVH but does not greatly improve prognosis.

Indexed as

ependymal ciliahydrocephalusinflammationintraventricular hemorrhagemicrogliaMLKLnecroptosisnecrostatin-1RIP1RIP3

Identifiers

PMID35662218
PMCPMC9165399
OpenAlexW4282932809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.